Add like
Add dislike
Add to saved papers

[Treatment Outcome of Anal Squamous Cell Carcinoma Treated with Radical Chemoradiotherapy].

We reviewed the clinical records of 7 patients with anal squamous cell carcinoma(SCC)to evaluate the effectiveness of radical chemoradiotherapy(CRT). The radiotherapy(RT)consisted of 40 Gy delivered to the pelvis and bilateral inguinal lesions, and a perianal booster dose of 20 Gy, in fractions of 2.0 Gy per day, 5 days per week. 5-fluorouracil(5-FU)and mitomycin C(MMC)were administered 3 times every 4weeks as standard chemotherapy. On the first day of RT, 750mg/m2 of 5-FU in the form of a continuous 24-hour infusion, for 5 days was administered. On the first day of chemotherapy, 10mg/ m2 of MMC was also administered as a single bolus infusion. One patient with a T3 tumor was administered oral TS-1 during RT because of advanced age. In the CRT group, there was 1 case each of T1 and T3, and the others were T2. Grade 2 adverse effects occurred in 5 patients, and Grade 3 in 2, but completion of CRT was achieved in all 7 patients. All patients had a complete response in the anal lesion after CRT. Three patients, including those with the T3 tumor treated with TS-1, developed recurrence of the anal lesion. Two patients with T2 tumors, who were treated with CRT comprising 5-FU and MMC, developed recurrence of the anal lesion more than 60 months after CRT. CRT is expected to be a safe and effective treatment to improve the prognosis for anal squamous carcinoma; however, sufficient and appropriate follow-up is necessary after a complete response.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app